What is Roth Capital’s Forecast for REVB FY2024 Earnings?

Revelation Biosciences, Inc. (NASDAQ:REVB) – Research analysts at Roth Capital increased their FY2024 EPS estimates for Revelation Biosciences in a note issued to investors on Wednesday, December 4th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($5.58) per share for the year, up from their prior forecast of ($6.22). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($7.48) per share. Roth Capital also issued estimates for Revelation Biosciences’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.01) EPS and FY2027 earnings at ($0.96) EPS.

Revelation Biosciences Stock Performance

Shares of NASDAQ REVB opened at $0.45 on Monday. Revelation Biosciences has a fifty-two week low of $0.42 and a fifty-two week high of $25.26. The company has a 50 day simple moving average of $0.79 and a two-hundred day simple moving average of $1.24. The company has a market capitalization of $1.93 million, a price-to-earnings ratio of -0.03 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.